| Bioactivity | EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting EGFRL858R/T790M/C797S and EGFRDel19/T790M/C797S mutants. EGFR kinase inhibitor 2 has the potential to address acquired resistance in the treatment of non-small cell lung cancer[1]. |
| Target | EGFRL858R/T790M/C797S, EGFRDel19/T790M/C797S |
| Name | EGFR kinase inhibitor 2 |
| Formula | C39H40N6O5 |
| Molar Mass | 672.77 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fan M et al. Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites. Bioorg Med Chem. 2023 Nov 10;96:117534. |
EGFR kinase inhibitor 2
CAS: F: C39H40N6O5 W: 672.77
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting EGFRL858R/T790M/C797S and EGFRDel19/T790M/C7
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.